Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BMS-986141 Form B vs Form A in Healthy Participants
NCT03035734Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of bms-986141 in thrombosis and coronary artery disease (CAD) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Bioavailability of BMS-986141 Form B relative to Form A at 4 weeks. Planned start Jan 2017; status: withdrawn.
02
Drugs
bms-986141
03
Conditions
thrombosiscoronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03035734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035734.